PRESS RELEASE – Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound
Dallas-Fort Worth (PRWEB) August 28, 2015 – Riordan-McKenna Institute founders, stem cell expert Neil Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies in Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound.
The case involved a 78-year-old male, who presented with a non-healing surgical wound following a right total knee replacement performed six weeks prior. The patient had not responded after 6 weeks of conservative wound care and the wound showed no signs of healing.
Dr. McKenna irrigated the wound in the operating room under pulse lavage and then placed two AlphaPATCH dry amniotic membranes (4 cm x 4 cm) over the wound before dressing it.
At the two-week follow-up visit, a central scab had formed. At four-weeks, the wound had completely scabbed over. At eight-weeks the scab had just fallen off and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.
The case report, entitled “Case Report Of Non-Healing Surgical Wound Treated With Dehydrated Amniotic Membrane” is published in the July issue of the Journal of Translational Medicine. Authors include Dr. Riordan, Dr. McKenna, Troy Chandler, PA-C, and Ben George, PA-C. This milestone in Dr. Riordan and Dr. McKenna’s ongoing study of biologic wound healing using amniotic tissue products and stem cells is the third peer reviewed journal article on regenerative medicine published by the Riordan McKenna Institute.
A common misconception is that dehydrated amniotic membrane products like AlphaPATCH contain live stem cells. Although dehydrated amniotic membrane does not contain any stem cells, it does contain a number of growth factors that promote healing and stimulate the body’s own stem cells to become activated and likely behave more similar to stem cells in a younger person.
“It’s gratifying to have this new tool in my toolbox. I treated conservatively and was getting nowhere. Even in a patient with a significant smoking history and decreased blood flow to his legs, we were able to achieve this result. Chronic wounds can be very frustrating for both the patient and the caregiver,” remarked Troy Chandler, PA-C, who participated in the patient’s treatment.
About Riordan-McKenna Institute (RMI)
RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.
RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.
*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/
801 E. Southlake Blvd.
Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154
About Amniotic Therapies
Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.
Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.
11496 Luna Rd. Suite 800
Tel: (972) 465-0496